Stephen V Liu: Report on real world efficacy and safety of amivantamab including off label use

Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at the Lombardi Comprehensive Cancer Centre, shared on X/Twitter:

“Report on real-world efficacy & safety of amivantamab in the Journal of Thoracic Oncology, including off-label use. In classical eGFR (estimated glomerular filtration rate) mutant Non-Small Cell Lung Cancer  (NSCLC), the Risk Ratio (RR) here was 36% (all post-TKI (Tyrosine kinase inhibitors), most given with osimertinib). No new safety signals with osimertinib (in this small cohort).”

In 7 points with atypical EGFR mutant NSCLC (all post TKI, median 4 prior lines), RR 86% and DCR 100%. In exon 20 insertion (47% post-TKI), RR 36%. Also, 25 points had concurrent radiation during amivantamab therapy with no safety signals observed.”

For the report, click here.
Source: Stephen V Liu/Twitter